Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.

Verywell Health's content is for informational and educational purposes only. Our website is not intended to be a substitute ...

Despite its vital role in "kick-starting" the immune response, IgD is arguably the least understood antibody, with little known about how it might participate in other parts of the immune system. A ...

1 Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy 2 Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy Dupilumab is a monoclonal antibody targeting ...

As the first IL-5-targeting monoclonal antibody in late-stage trials ... However, biologics like Dupixent (dupilumab) have paved the way for a new treatment paradigm, targeting specific ...

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody produced by recombinant DNA technology. It is formulated as an injectable solution for subcutaneous route of ...

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody produced by recombinant DNA technology. It is formulated as an injectable solution for subcutaneous route of ...